Green Rush Podcast: Dr. Joseph Tucker, Enveric Biosciences

dr. joseph tucker

Advertising Feature: This podcast is from a partner and was not produced by GreenState.

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. 

This week Anne Donohoe and Nick Opich talk to Dr. Joseph Tucker, CEO of Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogen therapeutics for the treatment of neuropsychiatric disorders. Dr. Tucker joins us to discuss the latest news and milestones for the company, including the selection of EB-003 as its lead candidate in its EVM 301 series, plus advice to the retail investor audience on continuing drug discovery investments in the psych space.

In this episode, Joe and our hosts also discuss psychedelic companies that are leveraging AI and how Enveric’s proprietary AI technology PsyAI™ integrates into the biotech’s research processes.

If you are interested in learning more about Joe and Enveric, visit the links in our show notes. Also, be sure to follow Enveric Biosciences on LinkedIn and X.

So, sit back and enjoy our conversation with Dr. Joseph Tucker, CEO of Enveric Biosciences (NASDAQ: ENVB).

Links, mentions, and socials:

Show Credits:

This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications.

Special thanks to our Program Director Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting or emailing You can also connect with us via our social channels:

X: @The_GreenRush

Instagram: @thegreenrush_podcast




An Advertising Feature means this post did not originate from the newsroom but rather was inspired by the sales department. It is not a paid post, but the sales team and their clients may benefit from increased readership of this relevant content.